Q-omics provides the consensus-scored HK3 profile across patient tissues and cancer cell-line models. HK3 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, HK3 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, HK3 protein abundance shows 27,514 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, and GBM as cancer lineages where HK3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HK3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HK3 survival associations across molecular data types. HK3 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (11) and mass-spec protein abundance (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HK3 RNA expression–survival associations across cancer types. High HK3 expression shows unfavorable associations in KIRC, ACC, LGG and GBM, but favorable associations in SKCM and HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for HK3 RNA expression.
This table summarizes HK3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for HK3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HK3 shows lower tumor expression in LUAD and higher tumor expression in KIRC, HNSC, THCA, COAD and KIRP. The KIRC box plot shows higher HK3 RNA expression in tumor versus normal tissue (log2 FC = +1.810, t-test p < 0.001).
This table shows molecular features associated with HK3 in patient tissues and cancer cell lines. In patient samples, HK3 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, HK3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and BLOOD_Leukemia.
